Expertise in
2
conditions

Thomas Winder

Oncology, Gastroenterology And Infectiology, Landeskrankenhaus Feldkirch
Feldkirch, AT 
Expertise in
2
conditions
Oncology, Gastroenterology And Infectiology, Landeskrankenhaus Feldkirch
Feldkirch, AT 

Overview

Thomas Winder practices practicing medicine in Feldkirch, Austria.

Mr. Winder is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatic Ductal Adenocarcinoma.

He is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Oncology, Gastroenterology and Infectiology, Landeskrankenhaus Feldkirch
Feldkirch, Austria
Other Locations
Vienna, Austria
Salzburg, 5020, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer
Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer
Enrollment Status: Completed
Publish Date: September 01, 2026
Intervention Type: Genetic, Diagnostic test
Study Phase: Not Applicable
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
Pilot Study: Biomarker Directed Treatment in Metastatic Colorectal Cancer
Pilot Study: Biomarker Directed Treatment in Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

77 Total Publications

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 28, 2026

Frequently Asked Questions about Thomas Winder

Is Thomas Winder a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Thomas Winder is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Thomas Winder participate in research or clinical trials?

Yes. Thomas Winder has published 77 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Thomas Winder's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Winder's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile